Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population

Bhatt, Rupal; Whittaker, Karl W; Appaswamy, Shivashankar; Desai, A; Fitt, Alan; Sandramouli, Soupramanien

doi:10.1038/sj.eye.6701515

Cited by 10 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was followed by Timolol, Brimonidine and Prostaglandin analogues. This observation was different from other studies in which ADR related to Dorzolamide was less frequent while Brimonidine (Bhatt et al) 12 and Latanoprost (M Alaei et al) 11 were found to be the most frequent offending medications. Since the ADR could also be related to preservatives (Used in the topical drug preparations), it is difficult to make a definite conclusion regarding this observation.…”

Section: Resultscontrasting

confidence: 55%

Impact of Adverse Drug Reactions of Topical Anti-Glaucoma Medications on the Vision-Related Quality of Life in Primary Open Angle Glaucoma

Sidhan¹,

Thankappan²,

C³

et al. 2017

jemds

View full text Add to dashboard Cite

BACKGROUNDAdverse drug reactions (ADR) to topical medications form an important cause for noncompliance in the long term management of glaucoma. This study was aimed to determine the different types of adverse drug reactions associated with glaucoma medications and their impact on the vision-related Quality of Life (vQOL) in patients with Primary Open Angle Glaucoma. MATERIALS AND METHODSPatients with Primary Open Angle Glaucoma, fulfilling the inclusion criteria were interviewed and data collected. Adverse drug reactions to topical anti-glaucoma medications were evaluated using the 'Comparison of Ophthalmic Medications for Tolerability Questionnaire' and quality of life related to vision was evaluated using the 'National Eye Institute Visual Function-25 Questionnaire'. Statistical analysis was performed using the SPSS version 22. The effect of ADR on the vQOL was analysed both by a univariate and multivariate analysis using a linear regression model. RESULTSThe study population included 115 patients (28% females) with mean age of 53.22 ± 11.46 years. At least one adverse drug reaction was reported in 71.2% of cases. Adverse drug reaction (ADR) was reported in nearly all patients on dorzolamide eye drops followed by timolol (74.1%), brimonidine (50%), bimatoprost (31.8%), latanoprost (39.3%) and travoprost (15%). The three most common adverse drug reactions reported were burning (60.75%), blurred vision (45.56%) and bitter taste (44.3%). The vision-related Quality scores in all subset domains were well above 50, the lowest being the general health and near activities domain. Significant association was noted between patients with ADR and low vQOL scores (P = 0.03) on multivariate analysis. CONCLUSIONAdverse drug reactions to topical anti-glaucoma medications were found to have a negative impact on the vision-related quality of life in glaucoma patients, emphasising the integration of proper patient education and counselling in the long-term management.

show abstract

Section: Resultscontrasting

confidence: 55%

Impact of Adverse Drug Reactions of Topical Anti-Glaucoma Medications on the Vision-Related Quality of Life in Primary Open Angle Glaucoma

Sidhan¹,

Thankappan²,

C³

et al. 2017

jemds

View full text Add to dashboard Cite

show abstract

“…For example, the poorly targeted nature of eye drops leads to extensive systemic exposure, which causes as much as 8-53% of glaucoma patients taking topical anti-glaucoma drugs to experience side effects [8, 9]. In the case of intravitreal administration of steroids, unwanted contact with the lens promotes the formation of cataract in 7 – 14% of patients [10, 11].…”

Section: Introductionmentioning

confidence: 99%

Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles

Kim

Edelhauser

et al. 2015

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

In this work, we tested the hypothesis that particles injected into the suprachoroidal space can be localized at the site of injection or broadly distributed throughout the suprachoroidal space by controlling polymeric formulation properties. Single hollow microneedles were inserted into the sclera of New Zealand White rabbits and injected non-biodegradable fluorescently tagged nanoparticles and microparticles suspended in polymeric formulations into the suprachorodial space of the eye. When formulated in saline, the particles were distributed over 29% - 42% of the suprachoroidal space immediately after injection. To spread particles over larger areas of the choroidal surface, addition of hyaluronic acid to make moderately non-Newtonian solutions increased particle spread to up to 100% of the suprachoroidal space. To localize particles at the site of injection adjacent to the ciliary body, strongly non-Newtonian polymer solutions localized particles to 8.3% – 20% of the suprachoroidal space, which exhibited a small increase in area over the course of two months. This study demonstrates targeted particle delivery within the suprachoroidal space using polymer formulations that spread particles over the whole choroidal surface or localized them adjacent to the ciliary body after injection.

show abstract

“…[11][12][13] Also, the poorly targeted nature of eye drops leads to extensive systemic exposure, which causes 8% to 53% of glaucoma patients taking topical antiglaucoma drugs to experience side effects. 14, 15 Poor patient compliance and low bioavailability of glaucoma drugs create the need for a better delivery method. 16 In this study, we introduced supraciliary delivery to target drug administration adjacent to the ciliary body to maintain high therapeutic drug levels at the site of pharmacologic action in the targeted tissue.…”

mentioning

confidence: 99%

Targeted Delivery of Antiglaucoma Drugs to the Supraciliary Space Using Microneedles

Kim

Edelhauser

Prausnitz

2014

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population

Cited by 10 publications

References 15 publications

Impact of Adverse Drug Reactions of Topical Anti-Glaucoma Medications on the Vision-Related Quality of Life in Primary Open Angle Glaucoma

Impact of Adverse Drug Reactions of Topical Anti-Glaucoma Medications on the Vision-Related Quality of Life in Primary Open Angle Glaucoma

Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles

Targeted Delivery of Antiglaucoma Drugs to the Supraciliary Space Using Microneedles

Contact Info

Product

Resources

About